作者
Akihiko Aoki,Katsusuke Naito,Osamu Hashimoto,Masatoshi Yamaguchi,Yoshihiro Hara,Baba Y,Takashi Wada,Keiji Joko,Kazuhiro Nagao,Gen-Ichiro Yamakawa,Ken-ichi Suyama,Kazuo Nagata,Hideyasu Matsuyama,Hiroshi Hirao,Yoshiyuki Shimizu,Hiroshi Hironaka,R. Isoyama,Masahiko Takemoto,Masahiro Tuchida,Kazutaka Shiraishi,Masahisa Kato,Yoriaki Kamiryo,Hiroyuki Harada,Tomoaki Otsuka,Hideo Mitsui,Takashi Nasu,Shigeaki Hayashida,Kazutaka Jojima,Sacho T,Yoshikazu Koshido,Noriaki Harada
摘要
We evaluated the clinical efficacy and safety of tamsulosin hydrochloride and cernitin pollen extract in 243 patients with urinary disturbance associated with benign prostatic hyperplasia. They were assigned randomly to 3 groups, oral tamsulosin hydrochloride, cernitin pollen extract and their combination were administered for 12 weeks. The international prostate symptom score, post-voided residual urine and uroflowmetrogram were obtained before and after treatment. The international prostate symptom score improved in each group and then the maximum flow rate and average flow rate also increased significantly in the tamsulosin hydrochloride-administered groups. In conclusion, the administration of only tamsulosin hydrochloride and the combination of tamsulosin hydrochloride and cernitin pollen extract seemed more effective then the administration of only cernitin pollen extract in the treatment of urinary disturbance associated with benign prostatic hyperplasia.